NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/05/2026
Voltar para busca
Dado oficial do USPTO
RHEACELL INNOVATIVE STEM CELL THERAPIES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
RHEACELL INNOVATIVE STEM CELL THERAPIES
ST13
US500000079307004Classe
5, 42, 44
Pedido
79307004
Registro
6696110
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
15/05/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42, 44
Data de depósito
11/12/2020
Data de registro
12/04/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
12/04/2022
Última transação
15/05/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
DE
Examinador
OSGOOD, KRYSTINA E
Unidade examinadora
N30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
RHEACELL GmbH & Co. KG
Representantes
Sean K. Owens Wood Herron & Evans LLP
Classificação técnica
Classes Nice
Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Drugsdrug delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceuticals; pharmaceutical and veterinary preparations for the treatment of skin diseasespharmaceutical and veterinary preparations for the treatment of vertigopharmaceutical and veterinary preparations for the treatment of nauseapharmaceutical and veterinary preparations for the treatment of vomitingpharmaceutical and veterinary preparations for the treatment of migrainepharmaceutical and veterinary preparations for the treatment of disease and disorders of the respiratory systemthe gastrointestinal systemthe endocrine systemthe cardiovascular systemthe nervous systemthe musculoskeletal systemthe urinary systemthe integumentary systemthe reproductive systempharmaceutical and veterinary preparations for the treatment of blood diseases and disorderspharmaceutical and veterinary preparationsantibioticsimmune suppressantsanti-inflammatory preparationspharmaceutical and veterinary preparations for wound healingpharmaceutical and veterinary preparations for anti-agingstem cells for medical and medical aesthetic purposesfibroblast cells for medical and medical aesthetic purposessurgical tissue implants comprised of living tissues obtained from fibroblasts; diagnostic agents for medical purposes; diagnostic preparations for medical and biomedical purposes; pharmaceutical cell preparations for medical use for the treatment of skin diseasesvertigonauseavomitingmigrainedisease and disorders of the respiratory systemdisease and disorders of the gastrointestinal systemdisease and disorders of the endocrine systemdisease and disorders of the cardiovascular systemdisease and disorders of the nervous systemdisease and disorders of musculoskeletal systemdisease and disorders of urinary systemdisease and disorders of integumentary systemdisease and disorders of the reproductive systemblood diseases and disorders; sterilizing substances for medical use; sterilizing substances for biomedical purposes; live implants comprising of live tissues for pharmaceutical purposes; biochemical and chemical productsbiochemical preparations for the treatment of skin diseases and chemical reagents for medical use; biochemical and chemical productsbiochemical preparations for the treatment of skin diseases and chemical reagents for pharmaceutical purposes; biochemical and chemical products for pharmaceutical or medical purposesbiochemical preparations for the treatment of skin diseasesvertigonauseavomitingmigrainedisease and disorders of the respiratory systemdisease and disorders of the gastrointestinal systemdisease and disorders of the endocrine systemdisease and disorders of the cardiovascular systemdisease and disorders of the nervous systemdisease and disorders of musculoskeletal systemdisease and disorders of urinary systemdisease and disorders of integumentary systemdisease and disorders of the reproductive systemblood diseases and disorders for diagnostic purposes; proteins being protein supplements for medical purposes; biological preparations for medical and veterinary purposespharmaceutical and veterinary preparationsall for external use for the treatment of skin diseaseswoundsulcersburns and surgical wounds; biologicalpharmaceutical and veterinary preparations for skin care for medical purposes; medical dressings; pharmaceutical preparations for wound treating and healing; biologicalpharmaceutical and veterinary preparations for the treatment of chronic woundsulcersburns and surgical wounds; stem cells for medical purposes; stem cells for veterinary purposes; stem cells for aesthetic purposes for medical use; somatic stem cell therapeutics for medical purposes; pharmaceutical implantsimplantable surgery human allograft bonesbiological bone tissue graftscells for medical usebiological bone marrow tissue; surgical implants comprised of living stem cells; surgical implants comprised of living fibroblasts tissue cells; biological human skin and bone tissue intended for subsequent implantation; cell growth media for culturing cells for medical purposes; pharmaceutical preparations for tissue regeneration; vascular grafts; living tissuevascular grafts; biotechnologically engineered tissue productstissue cells in sheet form and plasters for wound healing and treating burns for medical purposesbiological eye lens tissue graftsbiological bone tissue grafts
Classe 42
Pharmaceutical drug development; scientific and technological servicesnamely medical and pharmaceutical research services and technical research in the field of pharmaceutical studiesregenerative medicine and tissue engineering; research and development services in the fields of cell diagnostics and research and development services relating to new products for others in the field of therapy and surgical and medical instruments; industrial analysis and research servicesnamely analysis of industrial fluids and medical researchchemical analysis; scientific research for medical purposes in the field of stem cell therapies; stem cell research; scientific and medical research and development in the field of stem cells; scientific researchtesting and analysis services of the services of others to determine conformity with certification standards and in the field of regenerative medicine and tissue engineering; scientific research for medical purposes; medical research; research in the field of biotechnology; research in the field of gene therapy; research and development in the field of immunology; research and development in the field of antibodies; research and development in the field of antibody technology; research and development in the field of bacteriology; product research and development in the field of gene expression systems; research and development in the field of vaccines; research and development services for the pharmaceutical industry; research and development services in the field of biotechnology
Classe 44
Medical services; medical diagnostic services for carrying out tests and analyses; medical assistance; medical clinic services; hospital services; plastic and cosmetic surgery; medical therapiesstem cell therapy for treating medical conditions; medical services being human cells and tissue banksstem cell banks and bone marrow banksmedical services in the field of regenerative medicine and medical analysis services relating to the treatment of patients in the field of tissue engineering; medical services being banks of human tissue and stem cellsmedical services in the field of regenerative medicine and medical analysis services relating to the treatment of patients in the field of tissue engineering; medical services in the nature of stem cell banks for medical transplantation; medical services in the nature of cultured stem cell banks for medical transplantation
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
20/09/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
26/08/2022
FIMP
FINAL DISPOSITION PROCESSED
26/08/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/07/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
12/04/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
25/01/2022
PUBO
PUBLISHED FOR OPPOSITION
25/01/2022
GPNX
NOTIFICATION PROCESSED BY IB
22/01/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/01/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/01/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/01/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
21/12/2021
XAEC
EXAMINER'S AMENDMENT ENTERED
21/12/2021
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
21/12/2021
GNEA
EXAMINERS AMENDMENT E-MAILED
21/12/2021
CNEA
EXAMINERS AMENDMENT -WRITTEN
21/12/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/12/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/12/2021
RFNT
REFUSAL PROCESSED BY IB
28/06/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/06/2021
RFRR
REFUSAL PROCESSED BY MPU
09/06/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
08/06/2021
CNRT
NON-FINAL ACTION WRITTEN
07/06/2021
DOCK
ASSIGNED TO EXAMINER
03/06/2021
MAFR
APPLICATION FILING RECEIPT MAILED
26/03/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/03/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
18/03/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace RHEACELL INNOVATIVE STEM CELL THERAPIES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.